Role of TNF Family Ligands in Antitumor Activity of Natural Killer Cells

References

• Trinchieri G. Biology of natural killer cells. Adv. Immunol. 1989; 47: 187–376
   PubMed Web of Science ®Google Scholar
• Berke G. The binding and lysis of target cells by cytotoxic lymphocytes: Molecular and cellular aspects. Annu. Rev. Immunol. 1994; 12: 735–773
   PubMed Web of Science ®Google Scholar
• Podack E.R., Hengartner H., Lichtenheld M.G. A central role of perform in cytolysis?. Annu. Rev. Immunol. 1991; 9: 129–152
   PubMed Web of Science ®Google Scholar
• Golstein P., Ojcius D.M., Young J.D.-E. Cell death mechanisms and the immune system. Immunol. Rev. 1991; 121: 29–65
   PubMed Web of Science ®Google Scholar
• Chambers W.H., Brissette-Storkus C.S. Hanging in the balance: natural killer cell recognition of target cells. Chem. Biol. 1995; 2: 429–435
   PubMed Web of Science ®Google Scholar
• Lanier L.L. NK cell receptors. Annu. Rev. Immunol. 1998; 16: 359–393
   PubMed Web of Science ®Google Scholar
• Liu C.-C., Walsh C.M., Young J.D.-E. Perforin: structure and function. Immunol. Today 1995; 16: 192–201
   Google Scholar
• Smith M.J., Trapani J.A. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol. Today 1995; 16: 202–206
   PubMedGoogle Scholar
• Talento A., Nguyen M., Law S. Transfection of mouse cytotoxic T lymphocytes with an antisense granzyme A vector reduces lytic activity. J. Immunol. 1992; 149: 4009–4015
   PubMedGoogle Scholar
• Berestford P.J., Xia Z., Greenberg A.H., Lieberman J. Granzyme A loading induces rapid cytolysis and a novel form of DNA damage independently of caspase activation. Immunity 1999; 10: 585–594
   Google Scholar
• Medema J.P., Toes R.E.M., Scaffidi C., Zheng T.S., Flavell R.A., Melief C.J.M., Peter M.E., Offringa R., Kramer P.H. Cleavage of FLICE (caspase-8) by granzyme B during cytotoxic T lymphocyte-induced apoptosis. Eur. J. Immunol. 1997; 27: 3492–3498
   PubMedGoogle Scholar
• Hameed R., Schafer W., Sundersan V.D., Vaccarello L. Human T-lymphocyte serine proteases (granzymes) 1 1996; 2:and 3 mediated DNA fragmentation in susceptible target cells. Human Immunol., 49: 13–21
   Google Scholar
• Anel A., Gamen S., Alava M.A., Schmitt-Verhulst A.-M., Pineiro A., Naval J. Inhibition of CPP32-like proteases prevents granzyme B-and Fas-, but not granzyme A-based cytotoxicity exerted by CTL clones. J. Immunol. 1997; 158: 1999–2006
   Google Scholar
• Vujanovic N.L., Nagashima S., Herberman R.B., Whiteside T.L. Nonsecretory apoptotic killing by human NK cells. J. Immunol. 1996; 157: 1117–1126
   PubMed Web of Science ®Google Scholar
• Vujanovic N.L., Basse P., Herberman R.B., Whiteside T.L. Antitumor functions of natural killer cells and control of metastases. METHODS: A Companion to Methods in Enzymology 1996; 9: 394–408
   Google Scholar
• Whiteside T.L., Herberman R.B. The role of natural killer cells in immune surveillance of cancer. Current Opinion in Immunol. 1995; 7: 704–710
   PubMed Web of Science ®Google Scholar
• Berke G. Interactions of cytolytic T lymphocytes and target cells. Progr. Allergy 1980; 27: 69–133
   PubMedGoogle Scholar
• Berke G. The CTL's kiss of death. Cell 1995; 81: 9–12
   PubMed Web of Science ®Google Scholar
• Berke G. Unlocking the secrets of CTL and NIC cells. Immunol. Today 1995; 16: 343–346
   PubMedGoogle Scholar
• Henkart P.A. Lymphocyte-mediated cytotoxicity: Two pathways and multiple effector molecules. Immunity 1994; 1: 343–346
   PubMed Web of Science ®Google Scholar
• Podack E.R. Functional significance of two cytolytic pathways of cytotoxic T lymphocytes. J. Leukuc. Biol. 1995; 57: 548–552
   PubMed Web of Science ®Google Scholar
• Vujanovic N.L., Yasumura S., Hirabayashi H., Lin W.-C., Watkuns S., Herberman R.B., Whiteside T.L. Antitumor activitioes of subsets of human IL-2-activated natural killer cells in solid tissues. J. Immunol. 1995; 154: 281–289
   Google Scholar
• Nagashima S., Vujanovic N.L., Giorda R., Herberman R.B., Whiteside T.L. Killing mechanisms utilized by activated natural killer cells against solid tumor cell targets. FASEB J. 1995; 9: 1285–A221
   Google Scholar
• Gorelik E., Herberman R.B. Role of natural killer (NK) cells in the control of tumor growth and metastatic spread. Cancer Immunology: Innovative Approaches to Therapy. Martinus Nijhoff Publishers, Boston 1986, R. B. Herberman 152176
   Google Scholar
• Basse P., Herberman R.B., Nanmark U., Johanson R.B., Hokland M., Wasserman K., Goldfarb R.H. Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J. Exp. Med. 1991; 174: 479–488
   PubMed Web of Science ®Google Scholar
• Yasumura S., Lin W.-C., Hirabayashi H., Vujanovic N.L., Herberman R.B., Whiteside T.L. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells. Cancer Res. 1994; 54: 3808–3816
   PubMed Web of Science ®Google Scholar
• Okada K., Nanmark U., Vujanovic N.L., Watkins S., Basse P., Herberman R.B., Whiteside T.L. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer. Cancer Res. 1996; 56: 1599–1608
   PubMedGoogle Scholar
• Beutler B., van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994; 264: 667–668
   PubMed Web of Science ®Google Scholar
• Smith C.A., Farrah T., Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959–969
   PubMed Web of Science ®Google Scholar
• Gruss H.J. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int. J. Clin. Lab. Res. 1996; 26: 143–159
   PubMedGoogle Scholar
• Lotz M., Setareh M., von Kempis J, Schwarz H. The nerve growth factor/tumor necrosis factor receptor family. J. Leuk. Biol. 1996; 60: 1–7
   Google Scholar
• Singh A., Ni J., Aggarwal B.B. Death domain receptors and their role in cell demise. J. Interfer. Cytok. Res. 1998; 18: 439–450
   PubMedGoogle Scholar
• Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M.E. Apoptosis signaling by death receptors. Eur. J. Biochem. 1998; 254: 439–459
   PubMedGoogle Scholar
• Wallach D., Varfolomeev E.E., Malinin N.L., Goltsev Y.V., Kovalenko A.V., Boldin M.P. Tumor necrosis factor and Fas signaling mechanisms. Annu. Rev. Immunol. 1999; 17: 331–367
   PubMed Web of Science ®Google Scholar
• Nakano H., Oshima H., Chung W., Williams-Abbott L., Ware C.F., Yagita H., Okumura K. TRAF5, an activator of NF-KB and putative signal transducer for the lymphotoxin-β receptor. J. Biol. Chem. 1996; 271: 14661–14664
   PubMed Web of Science ®Google Scholar
• Force W.R., Cheung T.C., Ware C.F. Dominant negative mutants of TRAF3 reveal an important role for the coiled coil domains in cell death signaling by the lymphotoxin-β receptor. J. Biol. Chem. 1997; 272: 30835–30840
   PubMedGoogle Scholar
• Varfolomeev E.E., Boldin M.P., Goncharv T.M., Wallach D. A potential mechanism of “cross-talk” between the p55 tumor necrosis factor receptor and Fas/APO1: Proteins binding to the death domains of the two receptors also bind to each other. J. Exp. Med. 1996; 183: 1271–1275
   PubMed Web of Science ®Google Scholar
• Kinkhabwala M., Sehajpal P., Skolnik E., Smith D., Sharma V.K., Vlassara H., Cerami A., Suthanthiran M. A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J. Exp. Med. 1990; 171: 941–946
   PubMed Web of Science ®Google Scholar
• Monastra G., Cabrelle A., Zambon A., Rosato A., Macino B., Collavo D., Zanovello P. Membrane form of TNF-α induces both cell lysis and apoptosis in susceptible target cells. Cell. Immunol. 1996; 171: 102–110
   Google Scholar
• Abe Y., Horiuchi A., Osuka Y., Kimura S., Granger G.A., Gatanaga T. Studies of membrane-associated and soluble (secreted) lymphotoxin in human lymphokine-activated T-killer cells in vitro. Lymphokine Cytokine Res. 1992; 11: 115–121
   Google Scholar
• Ware C.F., Crowe P.D., Grayson M.H., Androlewicz M.J., Browning J.L. Expression of surface lymphotoxin and TNF on activated T, B and NK cells. J. Immunol. 1992; 149: 3881–3888
   PubMed Web of Science ®Google Scholar
• Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S., Nakao K., Nagata S. Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 1995; 154: 3806–3813
   PubMed Web of Science ®Google Scholar
• Lowin B., Hahne M., Mattmann C., Tshopp J. Cytotoxic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650–652
   PubMed Web of Science ®Google Scholar
• Kagi D., Vignaux F., Ledermann B., Burki K., Depraetere V., Nagata S., Hengartner H., Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528–530
   PubMed Web of Science ®Google Scholar
• Bossi G., Griffiths G.M. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nature Med. 1999; 5: 90–96
   PubMed Web of Science ®Google Scholar
• Martinez-Lorenzo M.J., Anel A., Gamen S., Monleon I., Lasierra P., Larrad L., Pineiro A., Alava M.A., Naval J. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J. Immunol. 1999; 163: 1274–1281
   PubMed Web of Science ®Google Scholar
• Nagata S. Apoptosis by death factor. Cell 1997; 88: 355–365
   PubMed Web of Science ®Google Scholar
• Kagi D., Ledermann B., Burki K., Zinkernagel R.M., Hengartner H. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu. Rev. Immunol. 1996; 14: 207–232
   PubMed Web of Science ®Google Scholar
• Glass A., Walsh C.M., Lynch D.H., Clark W.R. Regulation of the Fas lytic pathway in cloned CTL. J. Immunol. 1996; 156: 3638–3644
   PubMed Web of Science ®Google Scholar
• Stalder T., Hahn S., Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J. Immunol. 1994; 152: 1127–1133
   PubMed Web of Science ®Google Scholar
• Hahne M., Renno T., Schroeter M., Irmler M., French L., Bornand T., MacDonald H.R., Tschopp J. Activated B cells express functional Fas ligand. Eur. J. Immunol. 1996; 26: 721–724
   PubMed Web of Science ®Google Scholar
• Oyaizu N., Adachi Y., Hashimoto F., McCloskey T.W., Hosaka N., Kayagaki N., Yagita H., Pahwa S. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis. J. Immunol. 1997; 158: 2456–2463
   PubMed Web of Science ®Google Scholar
• Kiener P.A., Davis P.M., Rankin B.M., Klebanoff S.J., Ledbetter J.A., Starling G.C., Liles W.C. Human monocytic cells contain high levels of intracellular Fas ligand. J. Immunol. 1997; 159: 1594–1598
   PubMed Web of Science ®Google Scholar
• Badley A.D., Dockrell D., Simpson M., Schut R., Lynch D.H., Libson P., Paya C.V. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by Fast and tumor necrosis factor. J. Exp. Med. 1997; 185: 55–64
   PubMed Web of Science ®Google Scholar
• Suss G., Shortman K. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 1996; 183: 1789–1796
   PubMed Web of Science ®Google Scholar
• Lu L., Quian S., Hershberger P.A., Rudert W.A., Lynch D.H., Thomson A.W. Fas ligand (CD95L) and B7 expression on dendritic cells provide counter-regulatory signals for T cell survival and proliferation. J. Immunol. 1997; 158: 5676–5684
   PubMed Web of Science ®Google Scholar
• Arase H., Arase N., Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 1995; 181: 1235–1238
   PubMed Web of Science ®Google Scholar
• Montel A.M., Bochan M.R., Hobbs J.A., Lynch D.H., Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell. Immun. 1995; 166: 236–246
   PubMed Web of Science ®Google Scholar
• Oshimi Y., Oda S., Honda Y., Nagata S., Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J. Immunol. 1996; 157: 2909–2915
   PubMed Web of Science ®Google Scholar
• Mori S., Jewell A., Murakami-Mori K., Cavalcanti M., Bonavida B. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol. Immunother. 1997; 44: 282–290
   PubMed Web of Science ®Google Scholar
• Sayers T.J., Brooks A.D., Lee J.-K., Fenton R.G., Komschlies K.L., Wigginton J.M., Winkler-Pickett R., Wiltrout R.H. Molecular mechanisms of immune-mediated lysis of murine renal cancer: Differential contribution of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells. J. Immunol. 1998; 161: 3957–3965
   PubMed Web of Science ®Google Scholar
• Kashii Y., Giorda R., Herberman R.B., Whiteside T.L., Vujanovic N.L. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J. Immunol. 1999; 163: 5358–5366
   PubMed Web of Science ®Google Scholar
• Piazza C., Montani M.S.G., Moretti S., Cundari E., Piccolella E. CD4+ T cells kill C/D8+ T cells via Fas/Fas ligand-mediated apoptosis. J. Immunol. 1997; 158: 1503–1506
   PubMed Web of Science ®Google Scholar
• Lopez-Cepero M., Garcia-Sanz J.A., Herbert L., Riley R., Handel M.E., Podack E.R., Lopez D.M. Soluble and membrane-bound TNF-α are involved in the cytotoxic activity of B cells from tumor-bearing mice against tumor targets. J. Immunol. 1994; 152: 3333–3341
   PubMed Web of Science ®Google Scholar
• Takamuku K., Baba K., Arinaga S., Li J., Mori M., Akiyoshi T. Apoptosis in antibody-dependent monocyte-mediated cytotoxicity with monoclonal antibody 17–1A against human colorectal carcinoma cells: enhancement with interferon 7. Cancer Immunol. Immunother. 1996; 43: 220–225
   PubMed Web of Science ®Google Scholar
• Vitolo D., Vujanovic N.L., Rabinowich H., Schlesinger M., Herberman R.B., Whiteside T.L. Rapid IL-2-induced adherence of human natural killer cells. Expression of mRNA for cytokines and IL-2 receptors in adherent NK cells. J. Immunol. 1993; 151: 1926–1937
   Google Scholar
• Lee R.K., Spielman J., Zhao D.Y., Olsen K.J., Podack E.R. Perform, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J. Immunol. 1996; 157: 1919–1925
   PubMed Web of Science ®Google Scholar
• Thomas W.D., Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligund-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 1998; 161: 2195–2200
   PubMed Web of Science ®Google Scholar
• Mariani S.M., Krammer P.H. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur. J. Immunol. 1998; 28: 1492–1498
   PubMed Web of Science ®Google Scholar
• Kayagaki N., Yamaguchi N., Nakayama M., Kawasaki A., Akiba H., Okumura K., Yagita H. Involvement of TNF-relateda apoptosis-inducing ligand in CD4+ T cell-mediated cytotoxicity. J. Immunol. 1999; 162: 2639–2647
   PubMed Web of Science ®Google Scholar
• Phillips T.A., Ni J., Pan G., Ruben S.M., Wei Y.-F., Pace J.L., Hunt J.S. TRAIL (Apo-2L) and TRAIL receptors in human placentas: Implications for immune privilege. J. Immunol. 1999; 162: 6053–6059
   PubMed Web of Science ®Google Scholar
• Fanger N.A., Maliszewski C.R., Schooley K., Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 1999; 190: 1155–1164
   PubMed Web of Science ®Google Scholar
• Zamai L., Ahmad M., Bennet I.M., Azzoni L., Alnemri E.S., Perusia B. Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 1998; 188: 2375–2380
   PubMed Web of Science ®Google Scholar
• Tschopp J., Irmler M. Thome Inhibition of Fas death signals by FLIPs. Curr. Opin. Immunol. 1998; 10: 552–558
   PubMed Web of Science ®Google Scholar
• French L.E., Tschopp J. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J. Exp. Med. 1999; 190: 891–893
   PubMed Web of Science ®Google Scholar
• Van den Broek M.F, Kagi D., Ossendorp F., Toes R., Vamvakas S., Lutz W.K., Melief C.J.M., Zinkernagel R.M., Hengartner H. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 1996; 184: 1781–1790
   PubMed Web of Science ®Google Scholar
• Drappa J., Vaishnaw A.K., Sullivan K.E., Chu J.-L., Elkon K.B. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 1996; 335: 1643–1649
   PubMed Web of Science ®Google Scholar
• Davidson W.F., Giese T., Fredrickson T.N. Spontaneous development of plasmocytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 1998; 187: 1825–1838
   PubMed Web of Science ®Google Scholar
• Landowski T.H., Ou N., Buyksal I., Painter J.S., Dalton W.S. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90: 4266–4270
   PubMed Web of Science ®Google Scholar
• Smith M.J., Kelly J.M., Baxter A.G., Korner H., Sedgwick J.D. An essential role of tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J. Exp. Med. 1998; 188: 1611–1619
   Google Scholar
• Ito D., Back T.C., Shakhov A.N., Wiltrout R.H., Nedospasov S.A. Mice with a targeted mutation in lymphotoxin-α exhibit enhanced tumor growth and meta-stases: Impaired NK cell development and recruitment. J. Immunol. 1999; 163: 2809–2815
   PubMed Web of Science ®Google Scholar
• Hayward A.R., Levy J., Facchetii F., Notarangelo L., Ochs H.D., Etzioni A., Bonnefoy J.-Y., Cosyns M., Weinberg A. Cholangiopathy and tumors of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 1997; 158: 977–983
   PubMed Web of Science ®Google Scholar
• Ostenstand B., Giliani S., Mellbye O.J., Nilsen B.R., Abrahamsen T. A boy with X-linked hyper-IgM syndrome and natural killer cell deficiency. Clin. Exp. Immunol. 1997; 107: 230–234
   Google Scholar
• Djerbi M., Screpanti V., Catrina A.I., Bogen B., Biberfeld P., Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 1999; 190: 1025–1031
   PubMed Web of Science ®Google Scholar
• Medema J.P., Jong J. de, Hall T. van, Melief C.J.M., Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 1999; 190: 133–138
   Google Scholar